CTSO: CytoSorbents reports 4th quarter and 2024 financial results which showed impressive product revenue growth that was above our expectations.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
432 Views
CTSO: CytoSorbents reports 4th quarter and 2024 financial results which showed impressive product revenue growth that was above our expectations.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
385 Views
CTSO: CytoSorbents reports 4th quarter and 2024 financial results which showed impressive product revenue growth that was above our expectations.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
400 Views
CTSO: CytoSorbents reports 4th quarter and 2024 financial results which showed impressive product revenue growth that was above our expectations.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
386 Views
CTSO: CytoSorbents reports preliminary 4th quarter and 2024 financial results which showed impressive growth in the core international business that exceeded our expectations.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
448 Views